to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
| Condition(s) | Drug Drug Interaction (DDI) |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban |
| Who can participate | Inclusion Criteria: * Healthy subject aged ≥ 19 years to \< 65 years at the time of screening * Subjects who weigh ≥ 50 kg (or ≥ 45 kg in the case of females) with body mass index (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2 * Subjects who have voluntarily decided to participate after fully understanding the clinical trial based on the detailed explanation given, and have provided written informed consent before the screening procedure. Exclusion Criteria: * Subject who has a clinically significant history of disease in the liver, kidneys, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hematopoietic and oncological system, or cardiovascular system. * The Subject who has a clinically significant bleeding or a history of congenital or acqui |
| Ages | 19 Years to 64 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Onconic Therapeutics Inc. |
| Locations | Seongnam-si, Gyeonggi-do, South Korea |
| Start date | 2025-11-17 |
| NCT ID | NCT07265466 |
| Official listing | https://clinicaltrials.gov/study/NCT07265466 |